Episode Summary
John shares our take on the second half of April highlighting the health of Affordable Care Act (ACA) under the current administration and Humana’s statement to acquire and merge Curo Health with Kindred Healthcare.
Episode Notes
John shares our take on the second half of April highlighting the health of ACA under the current administration and Humana’s statement to acquire and merge Curo Health with Kindred Healthcare.
- The Centers for Medicare and Medicaid Services provided enrollment statistics for Healthcare.gov and the state-run exchanges created by the Affordable Care Act (ACA). In its last tax package, the Republican-led Congress zeroed out the individual mandate penalty—a cornerstone of the ACA. The Congressional Budget Office (CBO) estimated that 13 million people will lose or drop coverage as a result of this move over the next decade.
- Reuters reported that Humana, along with two private equity firms, will acquire Mooresville, N.C.-based Curo Health Services for $1.4 billion. Humana will merge Curo Health with the hospice business of Kindred Healthcare, which Humana agreed to acquire in December 2017.
Of Note: Our Take Narrations will be twice monthly after these inaugural episodes.
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
Recommended Next
Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes
Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports
Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations
Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.
